Could a hot flash drug also shield against breast cancer?
NCT ID NCT04821375
Summary
This small, early study tested whether a 6-month course of a drug combination (bazedoxifene plus estrogen), already approved for hot flashes, could change breast tissue in a way that might lower cancer risk. It involved 16 women experiencing menopause symptoms who were already at higher risk for breast cancer. Researchers used breast MRIs and mammograms to look for changes in tissue density and activity after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCREASED RISK FOR DEVELOPMENT OF BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.